Saturday, Apr 17, 2021 | Last Update : 09:00 AM IST

DCGI

DCGI extends shelf life of Covishield from 6 to 9 months

In a letter to the Serum Institute, DCGI said it is permitted to apply the shelf life of nine months to unlabelled vials available on hand

31 Mar 2021 12:25 PM

DCGI issues notice to Serum Institute over AstraZeneca's trial suspension

DGCI sought an immediate reply, saying else "it shall be construed that you have no explanation to offer and action will be taken"

10 Sep 2020 10:29 AM

Serum-Oxford COVID-19 vaccine gets DCGI grant for human trials in India

The panel had also recommended that the clinical trial sites which have been proposed for the study be distributed across India

03 Aug 2020 9:09 AM

Hetero launches COVID-19 drug Favivir at Rs 59 per tablet

The product is available from July 29 at all retail medical outlets across the country and will be sold only on prescription, it said

29 Jul 2020 2:04 PM

FabiFlu more economical, effective treatment option for COVID-19: Glenmark tells DGCI

Glenmark also denied making any claims that “favipiravir alone” is effective in treatment of mild-to-moderate COVID-19 patients

21 Jul 2020 3:38 PM

ADVERTISEMENT

Biophore gets DCGI nod to manufacture, export Favipiravir

CEO of Biophore said all starting materials for making favipiravir are either sourced locally or have been developed in-house for use

15 Jul 2020 6:59 AM

Hetero gets DCGI nod to launch Remdesivir for COVID-19 treatment

The drug will be available in 100 mg vial which will be administered intravenously in a hospital under healthcare practitioner supervision

21 Jun 2020 2:45 PM

8 Chinese companies get notices for poor quality of APIs

According to a pharma industry body, Indian pharma companies secure 70-75 per cent of APIs from China.

08 Jan 2018 2:06 AM

ADVERTISEMENT
ADVERTISEMENT